GHRP-2 vs Macimorelin
Research Verdict
Macimorelin is the stronger research reference for the stated comparison criteria. Macimorelin: FDA approved (2017) for adult GH deficiency diagnosis, Phase 3 validation trial vs.
Quick Answers
Which is better, GHRP-2 or Macimorelin?
Macimorelin is the stronger research reference for the stated comparison criteria. Macimorelin: FDA approved (2017) for adult GH deficiency diagnosis, Phase 3 validation trial vs.
What is the key difference between GHRP-2 and Macimorelin?
Macimorelin is an oral GH secretagogue approved solely as a diagnostic tool (single-dose test); GHRP-2 is an injectable secretagogue studied for repeated dosing - different routes and intended use patterns.
Evidence Comparison
Macimorelin: FDA approved (2017) for adult GH deficiency diagnosis, Phase 3 validation trial vs. insulin tolerance test (Garcia 2018, JCEM). GHRP-2: unapproved, no FDA-reviewed trials, but well-characterized GH dose-response in published pharmacological studies. Macimorelin wins decisively on regulatory evidence.
Evidence Context Favoring GHRP-2
Repeated-dose GH secretagogue research or pharmacological studies where injection route and higher GH potency are relevant.
Evidence Context Favoring Macimorelin
GH deficiency diagnosis, or research requiring an FDA-approved GH secretagogue reference standard.
Side-by-Side Snapshot
| Evidence grade | GHRP-2: Level C Macimorelin: Level A |
|---|---|
| Research status | GHRP-2: Preclinical Macimorelin: FDA Approved |
| Primary category | GHRP-2: Growth Hormone Macimorelin: Growth Hormone |
| Cited studies | GHRP-2: 2 Macimorelin: 2 |